Table 1.

Clinical characteristics of patients with earlier- and later-onset primary sclerosing cholangitis.

	Early onset	Late onset	p-value
Patients	183	32	–
Age at diagnosis [years]	30.1 ± 0.7	57.3 ± 1.3	–
Sex [male %]	133 (72.7)	17 (53.1)	0.02
IBD [yes/no]	122 (66.7)	19 (59.4)	0.4
Overlap with autoimmune hepatitis	11 (6.0)	0 (0.0)	0.2
Dominant stenosis	112 (61.2)	19 (59.4)	0.6
Dominant stenosis at first diagnosis	60 (32.8)	11 (34.4)	0.9
Laboratory parameters at baseline
Bilirubin [mg/dL]	0.9 ± 0.3	0.8 ± 0.4	0.9
ALT [IU/L]	117.9 ± 11.3	62.3 ± 36.7	0.03
AST [IU/L]	75.0 ± 6.9	44.1 ± 21.0	0.05
AP [IU/L]	298.5 ± 20.9	341.0 ± 52.7	0.2
GGT [IU/L]	320.0 ± 33.2	405.0 ± 61.3	0.6
Albumin [g/dL]	44.0 ± 0.7	41.5 ± 1.2	0.4
Mayo risk score	0.46 ± 0.1	0.69 ± 0.13	0.2
Development of CCA [%]	6 (3.3)	4 (12.5)	0.02
Development of colon cancer	11 (6.0)	2 (6.3)	0.4
Death [%]	7 (3.8)	7 (21.9)	<0.0001
OLT [%]	45 (24.6)	6 (18.8)	0.5
Death/OLT [%]	52 (28.4)	13 (40.6)	0.2
Survival free of liver transplantation [years]	20.8± 1.7	10.5 ± 0.6	<0.0001

Data are presented as n (%) or as means ± standard deviations.

IBD: inflammatory bowel disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AP: alkaline phosphatase; GGT: gamma-glutamyl transferase; CCA: cholangiocarcinoma; OLT: orthotopic liver transplantation